Abstract:Objective Earlier reports did not compare treatment regimens according to the nucleoside backbone.We studied a cohort of individuals who did not switch between stavudine and zidovudine.Evaluation of the efficacy and tolerability of various nucleoside-sparing combination antiretroviral therapy(cART) regimens.Methods Enrolled 362 ARV-na ve adults between September 2005 and April 2011,treated with zidovudine versus stavudine containing combination antiretroviral therapy.The laboratory results and signs were observed and analyzed with SPSS 11.5 statistical software package.Results Totally 231 patients were treated by zidovudine cART regimens,and 131patients were treated by stavudine cART regimens.No statistically significant difference was found between group zidovudine cART regimens and group stavudine cART regimens in terms of gender,age and the baseline of CD4 cell count.The average CD4+ T cell count increase at half year was 76.9±76.5 cells/mm3 and 114.5±99.2 cells/mm3 at one years with no significantly gain in the ZDV/d4T arm.Although after treatment there were a significant raising in sugur and serum triglycerides,there were no statistically significant difference in the ZDV/d4T arm.Thirty nine patients switch the regimens in group zidovudine cART regimens and 19 patients switch the regimens in group stavudine cART regimens in two years and the switch rate were no statictically significant difference.After two years treatmen,the switch rate due to the adverse event were raising in group stavudine cART regimens.Conclusion No statistically significant difference was found between group zidovudine cART regimens and group stavudine cART regimens in the efficacy and incidence of increase in sugar and serum triglycerides.The switch rate due to the adverse event were raising in group stavudine cART regimens after two years treatment.We should monitor ofen.

Comparative Study on Safety and Efficacy of Zidovudine Versus Stavudine Containing Combination Antiretroviral Therapy